An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.

A process for the preparation of an oral disintegrating tablet comprising the antihypertensive telmisartan and the tablet obtained by the process.

A method for the preparation of a composition includes dispersing particulate pimobendan in a molten carrier matrix to form particles coated with the carrier matrix, where the molten carrier matrix includes one or more pharmaceutically acceptable carriers selected from a polyglycolized glyceride, a polyethylene glycol, and combinations thereof, atomizing the dispersion of coated particles, and cooling and collecting the coated particles from the atomized dispersion.

Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.

The present invention relates to stable oral pharmaceutical compositions of sitagliptin base and processes for the preparation thereof.

The present invention relates to a stable pharmaceutical composition comprising omeprazole, its enantiomer, or its pharmaceutically acceptable salt, and sodium bicarbonate. Specifically, the present invention relates to a pharmaceutical composition with improved stability comprising a low dose of sodium bicarbonate, so that it has improved dissolution rate and bioavailability and also reduces side effects resulting from a high dose of sodium bicarbonate.

The present invention relates to a multiparticulate solid dosage form (1) which has an elastic texture and which contains a plurality of microcapsules (2) having a core (2a) and a shell (2b) that are embedded in an edible matrix (3). Microcapsules (2) contain an active ingredient which may be a pharmaceutical drug and/or a micronutrient. The multiparticulate solid dosage form of the invention is obtainable by a method wherein a mixture comprising water, microcapsules and starch particles is casted. The starch particles swell or dissolve only after casting.

The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically accetpable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity, or an obesity associated disorder.

A composition includes particles of pimobendan with an integral coating of a carrier matrix which serve to ensure a rapid dissolution of the active substance at each pH condition representing the gastrointestinal tract and therefore a reliable absorption, and a method of pimobendan microencapsulation using the spray congealing technology and incorporating the coated particles into oral formulations, for example into tablets.

Pharmaceutical compositions are provided which include enteric-coated pellets. The enteric-coated pellets include pure cellulose cores. A coating is present on the cores which contains 1) a proton pump inhibitor with benzimidazole structure in an amount greater than 10.5% by weight with respect to the total weight of the enteric-coated pellets, 2) one or more of lysine, histidine, and L-arginine, and 3) polyvinylpyrrolidone, wherein the dibasic amino acid is present in an amount less than or equal to 10% by weight in relation to the weight of the proton pump inhibitor. An enteric coating disposed over said coating. Enteric-coated pellets that contain pure cellulose cores having an average diameter between 150 and 300 microns have an average diameter between 350 and 590 microns and the enteric-coated pellets that contain pure cellulose cores with an average diameter between 300 and 500 microns have an average diameter between 500 and 710 microns.